Sienna Biopharma sinks after acne drug fails two trials (updated)

Sienna Biopharmaceuticals

30/07/2018 12:47

(Adds details on pipeline, CEO quote; updates share movement)
    July 30 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O 
said on Monday two pivotal trials testing its lead experimental
treatment for acne did not meet their main goals, sending its
shares tumbling nearly 28 percent before the bell.
    The topical treatment, SNA-001, when administered after
laser therapy to patients with moderate-to-severe acne vulgaris
did not show an additional benefit in reducing inflammatory
lesions, when compared to those on the control arm of the study,
the company said.   urn:newsml:reuters.com:*:nGNXbgwLbQ
    "We are disappointed by these results, which did not confirm
the findings from the previous proof of concept study," Chief
Executive Officer Frederick Beddingfield said in a statement.
    Results from a third acne trial are expected in the fourth
quarter of 2018, with the treatment being separately tested as a
therapy to reduce unwanted light-pigmented hair, the company
said. 
    Shares of Sienna, which went public about a year ago, were
down 22.9 percent at $12.11 in premarket trading.

 (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh
Kuber and Anil D'Silva)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))